EE200100698A - Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid - Google Patents

Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid

Info

Publication number
EE200100698A
EE200100698A EEP200100698A EEP200100698A EE200100698A EE 200100698 A EE200100698 A EE 200100698A EE P200100698 A EEP200100698 A EE P200100698A EE P200100698 A EEP200100698 A EE P200100698A EE 200100698 A EE200100698 A EE 200100698A
Authority
EE
Estonia
Prior art keywords
benzhydryl
azabicyclo
polymorphs
methoxybenzyl
oct
Prior art date
Application number
EEP200100698A
Other languages
English (en)
Estonian (et)
Inventor
John Meldrum Allen Douglas
Anthony Appleton Troy
Jon Gumkowski Michael
Joseph Muehlbauer David
Norris Timothy
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of EE200100698A publication Critical patent/EE200100698A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D453/00Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D455/00Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine
    • C07D455/02Heterocyclic compounds containing quinolizine ring systems, e.g. emetine alkaloids, protoberberine; Alkylenedioxy derivatives of dibenzo [a, g] quinolizines, e.g. berberine containing not further condensed quinolizine ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EEP200100698A 1999-06-22 2000-06-06 Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid EE200100698A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14023399P 1999-06-22 1999-06-22
PCT/IB2000/000756 WO2000078759A1 (en) 1999-06-22 2000-06-06 Polymorphs of crystalline (2-benzhydryl-1-azabicyclo[2,2,2]oct-3-yl)-(5-isopropyl-2-methoxybenzyl)-ammoniumchloride as nk-1 receptor antagonists

Publications (1)

Publication Number Publication Date
EE200100698A true EE200100698A (et) 2003-02-17

Family

ID=22490317

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100698A EE200100698A (et) 1999-06-22 2000-06-06 Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid

Country Status (35)

Country Link
US (1) US6262067B1 (cs)
EP (1) EP1187834A1 (cs)
JP (1) JP2003502425A (cs)
KR (1) KR20020030280A (cs)
CN (1) CN1390216A (cs)
AP (1) AP2001002367A0 (cs)
AR (1) AR024411A1 (cs)
AU (1) AU767336B2 (cs)
BG (1) BG106205A (cs)
BR (1) BR0011835A (cs)
CA (1) CA2375265A1 (cs)
CO (1) CO5190663A1 (cs)
CZ (1) CZ20014458A3 (cs)
DZ (1) DZ3055A1 (cs)
EA (1) EA004264B1 (cs)
EC (1) ECSP003538A (cs)
EE (1) EE200100698A (cs)
HR (1) HRP20010920A2 (cs)
HU (1) HUP0201694A3 (cs)
IL (1) IL146410A0 (cs)
IS (1) IS6161A (cs)
MA (1) MA26744A1 (cs)
MX (1) MXPA02000033A (cs)
NO (1) NO20016187D0 (cs)
NZ (1) NZ515348A (cs)
OA (1) OA11952A (cs)
PA (1) PA8496701A1 (cs)
PE (1) PE20010322A1 (cs)
PL (1) PL352899A1 (cs)
SK (1) SK18672001A3 (cs)
TN (1) TNSN00137A1 (cs)
TR (1) TR200103688T2 (cs)
UY (1) UY26211A1 (cs)
WO (1) WO2000078759A1 (cs)
ZA (1) ZA200110387B (cs)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387925B1 (en) * 1999-06-01 2002-05-14 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2.2.2) oct-3-yl amine citrate and their pharmaceutical compositions
US6939873B2 (en) 2000-07-26 2005-09-06 Taro Pharmaceuticals Industries Limited Non-sedating barbituric acid derivatives
US6756379B2 (en) 2001-07-26 2004-06-29 Taro Pharmaceutical Industries Ltd. Non-sedating barbiturate compounds as neuroprotective agents
US7683071B2 (en) * 2000-07-26 2010-03-23 Taro Pharmaceuticals Industries Ltd. Composition and method for improved bioavailability and enhanced brain delivery of 5,5-diphenyl barbituric acid
WO2004031191A1 (en) * 2002-10-04 2004-04-15 Merck Sharp & Dohme Limited Azabicyclic spiroether derivatives as receptor antagonists
EP2156839A1 (en) 2002-12-11 2010-02-24 Taro Pharmaceutical Industries Ltd. Method of treating movement disorders using barbituric acid derivatives
WO2006003651A2 (en) * 2004-07-02 2006-01-12 Taro Pharmaceutical Industries, Ltd A process for preparing 1-methoxymethyl-5,5-diphenylbarbituric acid
EP2081576A4 (en) * 2006-11-14 2010-06-30 Taro Pharmaceuticals North Ame METHOD FOR IMPROVING BIOAVAILABILITY FOR NON-EDMING BARBITURATES
UA102128C2 (en) * 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
CA3142271A1 (en) * 2019-06-03 2020-12-10 Biotheryx, Inc. Non-hygroscopic crystalline salts of a pyrazole compound, and pharmaceutical compositions and use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005525A1 (en) * 1988-11-23 1990-05-31 Pfizer Inc. Quinuclidine derivatives as substance p antagonists
WO1992021677A1 (en) * 1991-05-31 1992-12-10 Pfizer Inc. bibNUCLIDINE DERIVATIVES
EP0668863B1 (en) * 1992-11-12 1997-01-08 Pfizer Inc. Quinuclidine derivative as substance p antagonist
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis

Also Published As

Publication number Publication date
US6262067B1 (en) 2001-07-17
EP1187834A1 (en) 2002-03-20
HRP20010920A2 (en) 2003-02-28
IL146410A0 (en) 2002-07-25
WO2000078759A1 (en) 2000-12-28
AP2001002367A0 (en) 2001-12-31
AU4774500A (en) 2001-01-09
UY26211A1 (es) 2001-01-31
JP2003502425A (ja) 2003-01-21
PA8496701A1 (es) 2002-07-30
ZA200110387B (en) 2002-12-19
TR200103688T2 (tr) 2002-12-23
TNSN00137A1 (fr) 2002-05-30
OA11952A (en) 2006-04-13
AR024411A1 (es) 2002-10-02
DZ3055A1 (fr) 2004-03-27
SK18672001A3 (sk) 2002-08-06
AU767336B2 (en) 2003-11-06
KR20020030280A (ko) 2002-04-24
CN1390216A (zh) 2003-01-08
EA200101179A1 (ru) 2002-06-27
BG106205A (bg) 2002-07-31
NO20016187L (no) 2001-12-18
CO5190663A1 (es) 2002-08-29
HUP0201694A3 (en) 2002-10-28
NO20016187D0 (no) 2001-12-18
NZ515348A (en) 2003-07-25
PL352899A1 (en) 2003-09-22
CZ20014458A3 (cs) 2002-03-13
PE20010322A1 (es) 2001-03-14
MA26744A1 (fr) 2004-12-20
IS6161A (is) 2001-11-13
MXPA02000033A (es) 2002-07-02
HUP0201694A2 (en) 2002-09-28
ECSP003538A (es) 2002-01-25
CA2375265A1 (en) 2000-12-28
BR0011835A (pt) 2002-03-05
EA004264B1 (ru) 2004-02-26

Similar Documents

Publication Publication Date Title
SI1224175T1 (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
SI1224174T1 (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
AU6751301A (en) 1,3,8-triaza-spiro'4,5]decan-4-one derivatives as neurokinin receptor antagonists
ZA991413B (en) Substituted quinoxaline derivatives as interleukin-8 receptor antagonists.
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HUP0202034A3 (en) Heterocyclic substituted aminoazacycles useful as central nervous system agents
IL137936A0 (en) 2-arylethyl- (piperidin-4-ylmethyl) amine derivatives as muscarinic receptor antagonists
EE200100698A (et) Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-ammooniumk loriidi polümorfid kui NK-1 retseptori antagonistid
NZ513732A (en) Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
ID26223A (id) Antagonis reseptor vitronektin
IL142045A0 (en) Naphthalenecarboxamides as tachykinin receptor antagonists
EP1248607A4 (en) UROTENSIN II RECEPTOR ANTAGONISTS
AU1296899A (en) Phenyl-alkyl-imidazoles as h3 receptor antagonists
EE200100655A (et) Kristallilise (2-benshüdrüül-1-asabitsüklo[2,2,2]okt-3-üül)-(5-isopropüül-2-metoksübensüül)-amiintsitraadi polümorfid kui NK-1 retseptori antagonistid
IL142362A0 (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
GB0026327D0 (en) Thrombin receptor antagonists
IL139262A (en) Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists
GB9814737D0 (en) Fibrinogen receptor antagonists
AU2002354104A1 (en) Fused bicyclic pyridine derivatives as tachykinin receptor antagonists
HUP9800689A3 (en) Nk-1 receptor antagonists for the treatment of delayed emesis
ZA200108302B (en) Substituted bicyclic heteroaryl compounds as integrin antagonists.
AU2002334103A1 (en) Azabicyclic spiroether derivatives as receptor antagonists
HK1036065A (en) Benzimidazole compounds that are vitronectin receptor antagonists
HK1036795A (en) Ureidopiperidine derivatives as selective human nk3 receptor antagonists
AU2512800A (en) Alpha1-adrenergic receptor antagonists